We are excited to share that Ontario is the latest province to provide access to lanadelumab (TAKHZYRO) to HAE patients.

When the Ontario Ministry of Health issued its February Ontario Drug Benefit (ODB) formulary update, they announced that lanadelumab (TAKHZYRO) is now listed under the Exceptional Access Program (EAP) “for the routine prevention of attacks of hereditary angioedema (HAE) according to clinical criteria”. This is certainly welcome news to many HAE patients in Ontario who respond well to this treatment.

The reimbursement criteria for lanadelumab (TAKHZYRO) will be included on the list on the Ontario Drug Benefit Formulary website: Exceptional Access Program – Reimbursement Criteria for Frequently Requested Drugs; however, Ontario still hasn’t updated the website yet.

Once their website is updated, lanadelumab (TAKHZYRO) should appear under the generic name lanadelumab, under the section titled Blood Modifiers, which is where Icatibant is currently listed.

If you need further help, please contact your representative at OnePath, Takeda’s patient support program.